Erasca, a clinical-stage precision oncology company founded on UCSF professor Kevan Shokat's MedTech research, and focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the United States Food and Drug Administration has cleared an investigational new drug application for ERAS-3490, an orally available small molecule KRAS G12C inhibitor designed to have high central nervous system penetration for the treatment of KRAS G12C-mutated solid tumors, including non-small cell lung cancer.
